Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study

NCT01411150 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Huntington's Disease

Interventions

DRUG: Creatine Monohydrate

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]